Context: Testosterone (T) plus progestin combinations are the most promising hormonal male contraceptives. Nestorone (NES), a progestin without estrogenic or androgenic activity, when combined with T may be an excellent candidate for male contraception.
H ormonal methods to suppress sperm production in men should be effective, safe, reliable, affordable, and reversible (1) (2) (3) . Administration of testosterone (T) alone and T plus a progestin in men have shown contraceptive efficacy similar to female contraceptive methods where pregnancy rates in the partner had been reported to be very low (4 -7) . Recent retrospective analyses of available data from most hormonal male contraceptive studies showed that addition of a progestin to T increased the rate and extent of the suppression of spermatogenesis and younger men with lower initial sperm concentration and serum T levels showed faster suppression of spermatogenesis (8) . Recovery of spermatogenesis occurred in all men with a predictable time course after stopping the administration of T and progestins. The rate of recovery was faster with shorter duration of treatment and short-acting T preparations (9) .
Injectable esters such as injectable T ester and implants effectively suppress spermatogenesis at doses that produce relatively high serum T levels (4, 6, 7, 10) . Because progestins enhance the rate and extent of suppression of spermatogenesis compared with T alone, many combinations of T and progestins have been tested to seek the optimal combinations of specific hormones, formulations, dosages, and routes of administration (11) (12) (13) . Injectable progestins including depomedroxyprogesterone acetate and norethindrone enanthate and implants and oral preparations containing levonorgestrel and etonogestrel are shown to enhance the suppression of spermatogenesis by T injections or implants (14 -22) .
When transdermal T patches were administered with oral levonorgestrel, the suppression of spermatogenesis to severe oligozoospermia occurred in a quarter of participants (23, 24) . This limited suppression of sperm concentrations was attributed to lower serum T levels achieved with the patch. Daily application of T gel results in a dose-proportional increase in steady serum T levels in hypogonadal men and produces sustained relief of symptoms (25) (26) (27) (28) . When transdermal T gel was administered together with depo-medroxyprogesterone acetate in a male contraceptive trial, over 90% of the men became severely oligozoospermic (22) .
Nestorone (NES, 16-methylene-17␣-acetoxy-19-norpregn-4-ene-3, 20-dione, formerly referred to as ST 1435) is a 19-norprogesterone derivative without androgen or estrogen receptor binding activity. It is 2.9-fold more potent than progesterone in relative receptor binding activity and 90-fold more potent in inhibiting ovulation in female rats (29, 30) . Vaginal NES rings have been tested for female contraception (31) (32) (33) . Unlike other progestins that have not been developed into a transdermal delivery system, NES gel as a potential contraceptive has been studied in women but not in men (34) .
Our goal is to develop user-friendly transdermal hormonal male contraceptives. We investigated whether NES gel alone suppressed gonadotropins and whether NES gel had any additive effect to transdermal T gel on gonadotropin suppression, a surrogate marker of suppression of spermatogenesis, in a prospective, randomized, open-label, two-center trial.
Subjects and Methods

Subjects
Initially, 100 healthy male volunteers between the ages 18 and 50 yr (32.3 Ϯ 0.78 yr, mean Ϯ SEM) were recruited and enrolled at two academic health centers in Los Angeles and Seattle. Subjects underwent a screening phase to determine that they had normal baseline blood biochemistry, hematology, urinalysis, fasting lipid profiles, hormones, and semen analysis (sperm concentration Ͼ20 million/ml) according to the World Health Organization Manual for the Examination of Human Semen (35) . Eligible subjects were randomized using computer-generated numbers to five groups of 20 subjects each. Because in the initial study, T gel plus NES 2 or 4 mg groups failed to suppress both serum LH and FSH to 0.5 IU/liter or less in more than 50% of men, an additional 40 subjects were recruited and randomized in an extension study where T gel was administered with 6 and 8 mg/d NES gel. The protocol was approved by the Institutional Review Board of all three institutions (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center; University of Washington; and the Rockefeller University for Population Council).
Study medications
T gel 10 g (Testim) was provided by Auxilium (Malvern, PA) in tubes containing 5 g T gel and applied to both upper arms and shoulders. The formulation is a hydroalcoholic gel containing 1% T. Ten grams of Testim applied to the skin contains 100 mg T and delivers approximately 10 mg T to the systemic circulation (25) . NES gel was formulated and developed by the Population Council (New York, NY). The doses of 2, 4, and 6 mg/d NES were supplied as 1, 2, and 3 ml of 2 mg NES per gramg gel. For the 8-mg dose, 3 ml of 2.7 mg NES per gram gel were used. The NES gel was aspirated into syringes by the study staff and dispensed to the subjects who applied the gel daily to an area of 15 cm 2 on the abdomen.
Study design
The initial study was a prospective, randomized, open-label, twocenter trial. A total of 100 subjects were enrolled and randomized to one of five groups (20 per group with 10 per site): group 1, 2 mg NES/d; group 2, 4 mg NES/d; group 3, 10 g T gel/d; group 4, 10 g T gel plus 2 mg NES/d; and group 5, 10 g T gel plus 4 mg NES/d. Because the suppression of both gonadotropins to 0.5 IU/liter or less was suboptimal and lesser than anticipated, two additional groups of 20 men were randomized to receive higher dose of NES: group 6, 10 g T gel plus 6 mg NES gel/d, and group 7, 10 g T gel plus 8 mg NES/d. The total duration of treatment was about 20 d followed by a recovery period of about 4 wk (end of study visit on d 49 Ϯ 2). Compliance was determined by counting all empty and unused tubes or syringes and a diary on gel application was maintained by each subject.
Serum samples were obtained on d 1, 21, and 49 for SHBG, T, and free T. On d 1 and 21, five samples of blood were drawn at 15-min intervals for measurement of serum LH and FSH. On d 21, the serial samples for LH and FSH were drawn approximately 24 h after last application of the gel. These serial blood samples were collected to determine whether the pulsatile secretion of both gonadotropins was suppressed by treatment. Fasting blood samples for safety laboratory analyses were collected at screening and end of treatment visits. All serum samples were stored at Ϫ20 C until analyses and all samples from a subject were measured in one assay.
Hormone assays and safety laboratory tests
The safety laboratory tests were analyzed at the local laboratories. The screening semen analyses were performed according to standard methods (35) . Serum samples for NES concentration were measured by the Population Council using a validated RIA (32, 34) . Serum T, free T, and SHBG were measured by sensitive and specific RIA assays as previously described (36) . The adult male range for serum T was 9.4 -30.9 nmol/liter, free T 0.127-0.576 nmol/liter, and SHBG 10.8 -46.6 nmol/ liter. The intraassay coefficient of variations for LH and FSH fluoroimmunometric assays were 3.9 and 5.4%, respectively; and the interassay variations for LH and FSH were 6.8 and 9.8%, respectively (adult normal male ranges, LH 1.3-8.1 U/liter and FSH 1.4 -9.5 U/liter); and the lower limit of quantification was determined to be 0.1 IU/liter (26, 36) .
Statistical analyses
This was a dose-ranging study to measure the degree of gonadotropin suppression after daily self-application of T and NES gels. The primary efficacy outcome was the percentage of efficacy-evaluable men with both LH and FSH suppressed to 0.5 IU/liter or less after 20 d treatment. Secondary outcomes included mean percent changes from d 1-21 in LH, FSH, T, free T, and SHBG concentrations; percentage of efficacyevaluable men with both LH and FSH less than or equal to 1.0 IU/liter at d 21; and mean NES concentration at d 21 in those receiving NES). Five samples of blood were drawn for serum FSH and LH to increase the likelihood that this might reflect the mean serum LH and FSH levels. Serum LH and FSH concentrations were means of five samples taken on d 1 and 21, and other hormone concentrations were from a single serum sample.
A participant was defined as efficacy evaluable (compliant with study medications) if he 1) administered at least 80% of the medication doses during treatment, i.e. on at least 16 d; 2) had blood samples drawn within 48 h of the last administration; and 3) had detectable serum NES (Ն27 pmol/liter) at d 21 if he was in a NES group. Statistical assessments were performed with SAS version 9.1.3 (Cary, NC). Hormone levels and percent changes were summarized with medians and first to third quartile due to skewness. T plus NES groups were pairwise compared with the T-only group for these outcomes using Kruskal-Wallis tests, and the overall associations between these outcomes and dose were determined with Spearman correlations (37). Fisher's exact test was used for group comparisons for the percentage of men with low gonadotropins. Changes in safety laboratory parameters from screening to d 21 were summarized with medians using all 140 enrolled subjects and assessed for significance with Wilcoxon signed-rank tests. Numbers of men outside safety parameter reference ranges were compared between screening and d 21 using Mantel-Haenszel statistics (37) .
The study size was based on the desired precision and lower bound for the percentage of men with suppressed gonadotropins that would warrant a subsequent study of spermatogenesis suppression with longer duration of treatment. For each treatment group, the 95% confidence bounds for a percentage of gonadotropin suppression would not exceed Ϯ25%. Anticipated longer-term spermatogenesis suppression in men with gonadotropin suppression at approximately 21 d was estimated from recently completed longer studies of T alone or in combination with levonorgestrel or with the GnRH antagonist, acyline (19, 22, 24, 36, 38, 39) . In these studies combined, 96% (92%) of men who achieved suppression of both gonadotropins to less than 0.5 IU/liter (Ͻ1.0 IU/liter) after 3-4 wk treatment later achieved suppression of sperm concentration to 1 million/ml or less, the defined goal for male contraceptive clinical trials (40) . Table 1 categorizes the reasons for excluding 21 subjects from efficacy analyses (top) and summarizes the pretreatment characteristics for the 119 remaining evaluable men (bottom). Sixteen subjects were considered not efficacy evaluable because they did not meet the criteria for being compliant with study medications. Another five subjects were withdrawn from the study: one stopped treatment after experiencing panic attacks (classified as mild and possibly related to study medication in the T plus TABLE 1. Reasons for exclusion of subjects for analyses and baseline characteristics of evaluable subjects J Clin Endocrinol Metab, July 2009, 94(7):2313-2320 jcem.endojournals.orgNES 8 mg group), one after acne (classified as moderate and probably related to study medications in the T alone group), one after nausea and diarrhea, one subject withdrew consent on advice of a family member, and one subject was withdrawn after taking a double dose of NES. Median rate of compliance, as ascertained by returned tubes and syringes, was 95% (first to third quartiles, 91-95%), with 82% of men taking at least 90% of scheduled doses. These rates did not differ significantly among the treatment groups. The 140 randomized men were 77% Caucasian and had median age, weight, and body mass index of 30 yr (range 18 -50), 82.7 kg, and 26.1, respectively. There were no significant differences in these characteristics among the treatment groups although the T plus NES 6 mg group tended to weigh less.
Results
Characteristics of study participants
Effect on serum gonadotropins
There were significant decreases in LH and in FSH in all groups (P Ͻ 0.05) (Fig. 1, A and B) . Significantly greater decreases in LH and FSH were seen (P Ͻ 0.0001) as NES was added in increasing doses, ultimately attaining over 90% median decreases of both gonadotropins with T gel plus 6 or 8 mg NES gel ( Table 2 ). The percentage of men with both LH and FSH less than 0.5 or 1 IU/liter was less than 13% for NES gel-only groups and less than 32% in T gel-only group but increased significantly (P Ͻ 0.0001) as NES gel was added in increasing doses to 68.8 and 81.3%, respectively, in the 6-and 8-mg/d NES plus T gel groups. The additive effect of NES gel, when used in combination with T gel 10 g compared with T 10 g alone, was observed only when the NES dose was at least 6 mg. When NES 6 or 8 mg/d NES gel was added to 10 g T gel, a greater percent decrease in serum gonadotropin levels (P Ͻ 0.05) and more subjects suppressed serum gonadotropin levels to less than 0.5 or 1 IU/liter (P Ͻ 0.05) when compared with T gel alone ( Table 2 ). In the T gel plus Nes 8 mg group, serum LH and FSH levels were below the lower limit of quantification in 11 of 16 subjects, and spikes of LH secretion were observed in only two of the remaining five subjects who had measurable LH levels.
TABLE 2. Effect of NES and T gel on serum gonadotropins
Serum NES concentrations
When applied with T 10 g, median serum NES levels at d 21 significantly (P Ͻ 0.0001) increased with application of increasing amounts of NES gel (Fig. 2) , showing a dose-related response. Higher serum NES levels at d 21 were significantly associated with greater percent reductions in both LH (Spearman correlation ϭ 0.50; P Ͻ 0.0001) and FSH (Spearman correlation ϭ 0.60; P Ͻ 0.0001).
Serum total and free T and SHBG
Large inter-individual variations in serum total and free T concentrations were observed after T gel application (Fig. 3, A  and B ). There were no significant differences in serum total and free T and SHBG among treatment groups at d 1 ( Table 1) . Both NES gel-only groups showed significant decreases in serum total and free T concentrations (P Ͻ 0.05) from d 1-21as a result of the suppression of gonadotropins. The T gel-only group and T gel plus NES gel 4 mg group showed significant increases from d 1-21 in serum total T levels (P Ͻ 0.05). There was no trend of changes in serum T with increasing NES dosage (P ϭ 0.46; Fig.  3A ). Serum SHBG changes were minor and nonsignificant for all treatment groups (Fig. 3C) .
Safety laboratory monitoring parameters
Twenty-three percent of men had at least a 1-kg loss in body weight, and 19% had at least a 1-kg gain, with a median nonsignificant decrease of 0.2 kg (P ϭ 0.39). No significant changes from screening to d 21 were observed for prostate-specific antigen, hemoglobin and hematocrit, liver transaminases, alkaline phosphatase, urea nitrogen, creatinine, and triglycerides (supplemental Table 1 , published as supplemental data on The Endocrine Society's Journals Online web site at http://jcem. endojournals.org). Median total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol concentrations were significantly (P Ͻ 0.01) decreased by 7, 5, and 10%, respectively, and total to HDL cholesterol ratio significantly increased by 4% (P ϭ 0.002) in all groups combined. The decreases in HDL were significant and more than 9.5% in all of the five groups receiving T gel but were less than 4% and nonsignificant in the two groups receiving only NES gel. At screening, 50 of 140 subjects had serum HDL cholesterol below the reference range compared with 82 of 140 subjects at d 21 (or end of study visit for those who dropped from the study), whereas 17 and five subjects had serum HDL levels above the reference ranges at screening and d 21, respectively (P Ͻ 0.0001, supplemental Table 3 ).
Adverse events
There were no serious adverse events. Vital signs and physical examination did not change significantly during the study. Acne was reported in 10% of the men, and only one was in a NES-only group. Pruritis was reported as possibly and probably related to study medication in 4.6% of subjects both in the T and the NES groups. Only 2.1% of subjects had erythema at the application site with both T and NES gels. One subject discontinued because of acne. Other common adverse events were headache in 5% and nausea in 5% of subjects. Most adverse events occurred in all treatment groups except subject-reported decreased libido (4.3%), which was reported only in the two NES gel-alone groups and probably related to the suppressed serum T levels. There was one subject in the T gel plus NES 4 mg group whose serum LH and FSH concentrations remained less than 1 IU/ liter 1 month after stopping application of the gels, although his serum T was within the reference range. No other safety parameters or semen samples were collected at the end of study visit.
Discussion
NES is not active orally but shows a high antiovulatory effect in female hormonal contraception studies when given via nonoral routes such as transdermal gel and vaginal ring (32) (33) (34) 41) . In contrast to the androgenic progestins, levonorgestrel or desogestrel, NES does not bind to either the androgen receptor or SHBG. It has neither estrogenic nor glucocorticoid activity. In female rabbits and rats, NES was more potent than levonorgestrel or desogetrel in standard tests for progestational activity. In castrated male rats, NES has no detectable androgenic actions on the prostate and the levator ani muscle compared with levonorgestrel. In male rats, NES failed to show significant suppression of serum LH compared with T and levonorgestrel (29) . We tested NES (using about 2-to 4-fold the doses used in females) in healthy volunteers with the goal of developing transdermal NES gel together with T gel as a user-controlled, provider-independent (self-administered) method of male contraception. We elected to conduct this trial before performing a spermatogenesis suppression study to determine the effective dose of NES for gonadotropin suppression and for an additive effect when administered together with the selected T gel dose.
We showed that in men, transdermal NES gel at about two to four times the dose used in females suppressed both serum LH and FSH significantly although to a lesser extent than T gel alone. In the NES gel-alone groups, the decrease in gonadotropins resulted in significant decreases in serum T levels and self-reported decreased libido in six subjects. When increasing doses of NES were administered together with T transdermally, serum NES showed a dose-proportional rise, resulting in a dose-proportional increase in the suppression of both gonadotropins. At higher doses tested (NES 6 or 8 mg/d) in combination with T gel, the suppression of gonadotropin levels and the number of men that suppressed to very low levels were significantly greater than T gel alone. Many of these men had nondetectable serum LH and FSH. It should be noted that the suppression of gonadotropins was assessed about 24 h after the application of the gels when the negative feedback effects of the T and NES may not be maximal. The data provide evidence that although NES on its own has weak to moderate gonadotropin suppressive activity in men, when used in combination with T, the additive effect is significant.
In this study, T gel alone suppressed gonadotropins to very low levels (Յ0.5 or 1 IU/liter) in 20 -30% of men. Serum T concentrations achieved with transdermal T preparations were rather variable and significantly increased in only two of the five groups of men that received T gel. In a previous male contraceptive study using T gel 10 g/d together with depo-medroxyprogesterone acetate, serum T levels were variable and reached rather high levels in some subjects (22) . The dose of the T gel used (10 g T gel delivers about 10 mg of T per day to the body) is at the upper limit of the daily T production rate in healthy adult men (42) . We chose this dose of T gel to show that even with a high replacement dose of T we could demonstrate a significant enhancement of gonadotropin suppression by the addition of NES; we therefore speculate that the combined treatment of 10 g T gel plus at least 6 mg or more NES gel per day will have major suppressive effects on spermatogenesis. Once this dose of T plus NES gel showed efficacy in suppression of sperm production, then the dose of the T gel might be lowered to avoid high serum T levels observed in some subjects that might result in increased hemoglobin/hematocrit and decreased serum HDL cholesterol levels.
The combined treatment had few adverse effects. Mild acne developed in 10% of subjects; one subject (T gel-alone group) had moderately severe acne and stopped participating in the study. Mild local erythema and pruritis occurred in a small number of subjects, which did not result in subject discontinuation. Serum total and LDL cholesterol decreased by 5-7%, but HDL cholesterol decreased significantly by 10%. The decrease in HDL cholesterol levels occurred in all T gel treatment groups but less in the NES-alone groups suggesting that the decrease is likely secondary to the T administered. These changes are small and may not be clinically relevant. Longer-term studies are required to confirm the decrease in HDL cholesterol which was also noted in hypogonadal men treated with T gel (28) . Whether the decreases in HDL cholesterol in the presence of smaller but concomitant decrease LDL cholesterol levels would increase the risk of cardiovascular risks remains controversial (43, 44) .
In conclusion, in this study, we demonstrated that NES alone had a moderate gonadotropin-suppressive activity in men. When combined with a relatively high dose of T gel, NES (at doses of Ͼ6 mg/d) had additive effect on the suppression of gonadotropins. Previous studies showed suppression of gonadotropins within 3-4 wk after administration of T and progestins equate severe suppression of spermatogenesis when the combination was used for a longer period of time. We are currently planning to conduct a spermatogenesis suppression study using T gel 10 g with 8 mg or higher doses of NES. If the combination proves efficacious, future studies will aim to develop this combination into a new provider-independent method using a daily combined androgen and progestin transdermal preparation for male contraception.
